JP2020520382A - 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 - Google Patents

中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 Download PDF

Info

Publication number
JP2020520382A
JP2020520382A JP2020513491A JP2020513491A JP2020520382A JP 2020520382 A JP2020520382 A JP 2020520382A JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020513491 A JP2020513491 A JP 2020513491A JP 2020520382 A JP2020520382 A JP 2020520382A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520382A5 (enExample
Inventor
キム クレイマー，
キム クレイマー，
チュン ナイ−コン，
チュン ナイ−コン，
オーレ バーズガード，
オーレ バーズガード，
サン−ペドロ， クラウス ジェイ． メラー
サン−ペドロ， クラウス ジェイ． メラー
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
ワイ−マブス セラピューティクス， インコーポレイテッド
ワイ−マブス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター, ワイ−マブス セラピューティクス， インコーポレイテッド, ワイ−マブス セラピューティクス， インコーポレイテッド filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2020520382A publication Critical patent/JP2020520382A/ja
Publication of JP2020520382A5 publication Critical patent/JP2020520382A5/ja
Priority to JP2022195529A priority Critical patent/JP2023016969A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020513491A 2017-05-12 2018-05-14 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用 Pending JP2020520382A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022195529A JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505558P 2017-05-12 2017-05-12
US62/505,558 2017-05-12
PCT/US2018/032559 WO2018209346A1 (en) 2017-05-12 2018-05-14 Use of anti-b7h3 antibodies for treating cancer in the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022195529A Division JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Publications (2)

Publication Number Publication Date
JP2020520382A true JP2020520382A (ja) 2020-07-09
JP2020520382A5 JP2020520382A5 (enExample) 2021-07-26

Family

ID=64102794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513491A Pending JP2020520382A (ja) 2017-05-12 2018-05-14 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用
JP2022195529A Pending JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022195529A Pending JP2023016969A (ja) 2017-05-12 2022-12-07 中枢神経系におけるがんを処置するための抗ｂ７ｈ３抗体の使用

Country Status (11)

Country Link
US (2) US20200197546A1 (enExample)
EP (1) EP3635012A4 (enExample)
JP (2) JP2020520382A (enExample)
KR (1) KR20200008580A (enExample)
CN (1) CN110799542A (enExample)
AU (1) AU2018265888A1 (enExample)
BR (1) BR112019023776A2 (enExample)
CA (1) CA3062335A1 (enExample)
EA (1) EA201992683A1 (enExample)
RU (1) RU2019140833A (enExample)
WO (1) WO2018209346A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113853220A (zh) * 2019-03-11 2021-12-28 生物相容英国有限公司 用于中枢神经系统肿瘤治疗的放射性微球
EP4022313A1 (en) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
WO2021190586A1 (zh) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3抗体-依喜替康类似物偶联物及其医药用途
CN117024590A (zh) * 2020-04-22 2023-11-10 复星凯特生物科技有限公司 抗人b7-h3的单克隆抗体及其应用
EP4138931A1 (en) 2020-04-24 2023-03-01 Y-Mabs Therapeutics, Inc. B7h3 antibodies with chelators
CN112961241B (zh) * 2020-06-30 2022-04-22 广州百暨基因科技有限公司 抗b7h3抗体及其应用
WO2022167052A1 (en) * 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies
KR20230145038A (ko) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
US20240199750A1 (en) 2021-03-26 2024-06-20 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
KR20240019297A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
US20240392007A1 (en) * 2021-09-27 2024-11-28 Shenghe (China) Biopharmaceutical Co., Ltd. Heterodimeric protein and application thereof
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
WO2024008039A1 (zh) * 2022-07-08 2024-01-11 盛禾(中国)生物制药有限公司 一种异源二聚体融合蛋白及其应用
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2010523478A (ja) * 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2016106004A1 (en) * 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033225A2 (en) * 2014-08-27 2016-03-03 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER TREATMENT REVIEWS, vol. 36, JPN6023001551, 2010, pages 307 - 317, ISSN: 0004967581 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 35 (15_suppl), JPN6023001552, 20 May 2017 (2017-05-20), pages 10545, ISSN: 0004967582 *
JOURNAL OF NEURO-ONCOLOGY, vol. 97, JPN6022023025, 2010, pages 409 - 418, ISSN: 0004967580 *

Also Published As

Publication number Publication date
KR20200008580A (ko) 2020-01-28
EA201992683A1 (ru) 2020-04-23
US20200197546A1 (en) 2020-06-25
CA3062335A1 (en) 2018-11-15
US20240415990A1 (en) 2024-12-19
JP2023016969A (ja) 2023-02-02
RU2019140833A (ru) 2021-06-15
AU2018265888A1 (en) 2019-11-21
EP3635012A1 (en) 2020-04-15
CN110799542A (zh) 2020-02-14
RU2019140833A3 (enExample) 2022-02-07
WO2018209346A1 (en) 2018-11-15
EP3635012A4 (en) 2020-12-30
BR112019023776A2 (pt) 2020-07-28

Similar Documents

Publication Publication Date Title
US20240415990A1 (en) Use of anti-b7h3 antibodies for treating cancer in the central nervous system
JP7592654B2 (ja) ヒト化抗カリクレイン－２抗体
US12383637B2 (en) Therapeutic agents and uses thereof
Kramer et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
JP5155356B2 (ja) モノクローナル抗体ｈＰＡＭ４
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
CN116271117A (zh) Cd8成像构建体及其使用方法
Reardon et al. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients
Bailey et al. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes
Vuillez et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial
Reulen et al. Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments
Goto et al. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
Dijkers et al. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
He et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
US20230398242A1 (en) Fibroblast Activation ImmunoPET for Detection of Fibrosis Activity
Zalutsky et al. Targeted radiotherapy of central nervous system malignancies
HK1201454B (en) Therapeutic agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230118